Regentis Biomaterials (RGNT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Regentis Biomaterials (RGNT) is Moderate Underperform.

The composite score behind that read is -0.51, weighing +0.00 of bullish evidence against -0.50 bearish.

Regentis Biomaterials last closed at $1.65, -1.20% on the session.

Against the IVW growth benchmark the position is -1.81% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

17 graded predictions for RGNT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Regentis Biomaterials is classified under Health Care / Biotechnology, with a market capitalisation of $11.73M.

StockMap tracks Regentis Biomaterials as the 335th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Regentis Biomaterials ranks 356th of 365 in the group, against a group median of -0.21.